Review



igg3 reference antibodies  (Athens Research)


Bioz Verified Symbol Athens Research is a verified supplier
Bioz Manufacturer Symbol Athens Research manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Athens Research igg3 reference antibodies
    FLU-v IgG1 ( A ) and <t>IgG3</t> ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.
    Igg3 Reference Antibodies, supplied by Athens Research, used in various techniques. Bioz Stars score: 94/100, based on 23 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igg3 reference antibodies/product/Athens Research
    Average 94 stars, based on 23 article reviews
    igg3 reference antibodies - by Bioz Stars, 2026-03
    94/100 stars

    Images

    1) Product Images from "FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans"

    Article Title: FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans

    Journal: Vaccines

    doi: 10.3390/vaccines13111084

    FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.
    Figure Legend Snippet: FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.

    Techniques Used: Whisker Assay, MANN-WHITNEY

    Fold increase in FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups from day 0 to days 42 and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo (n = 26), and non-adjuvanted placebo ( n = 32). Box and whiskers plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. Fold change in IgG1 concentrations on day 42 and 180 is defined as the ratio of day 42 to day 0 and the ratio of day 180 to day 0, respectively. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between day 42 and 180 within each group. Significant differences are shown.
    Figure Legend Snippet: Fold increase in FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups from day 0 to days 42 and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo (n = 26), and non-adjuvanted placebo ( n = 32). Box and whiskers plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. Fold change in IgG1 concentrations on day 42 and 180 is defined as the ratio of day 42 to day 0 and the ratio of day 180 to day 0, respectively. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between day 42 and 180 within each group. Significant differences are shown.

    Techniques Used: MANN-WHITNEY

    Antibody-mediated NK cell activation after adjuvanted and non-adjuvanted FLU-v vaccination. For this analysis, a subset of paired samples ( n = 50) from day 0 and day 42 was selected based on high IgG1 and IgG3 fold increases. Data from the following groups are shown: adjuvanted FLU-v ( n = 32), non-adjuvanted FLU-v ( n = 16), and non-adjuvanted placebo ( n = 2). Antibody-dependent NK cell activation, or percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, was measured in response to antibodies immobilized by plate-bound FLU-v ( A ) or non-related peptides used as negative controls ( B ). Medians ± 95% confidences intervals are shown. The Wilcoxon signed-rank sum test was used to compare differences between time points within each vaccine group. A Bonferroni test was used to correct for multiple comparisons, with a p value < 0.025 considered significant.
    Figure Legend Snippet: Antibody-mediated NK cell activation after adjuvanted and non-adjuvanted FLU-v vaccination. For this analysis, a subset of paired samples ( n = 50) from day 0 and day 42 was selected based on high IgG1 and IgG3 fold increases. Data from the following groups are shown: adjuvanted FLU-v ( n = 32), non-adjuvanted FLU-v ( n = 16), and non-adjuvanted placebo ( n = 2). Antibody-dependent NK cell activation, or percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, was measured in response to antibodies immobilized by plate-bound FLU-v ( A ) or non-related peptides used as negative controls ( B ). Medians ± 95% confidences intervals are shown. The Wilcoxon signed-rank sum test was used to compare differences between time points within each vaccine group. A Bonferroni test was used to correct for multiple comparisons, with a p value < 0.025 considered significant.

    Techniques Used: Activation Assay, Flow Cytometry

    Correlation between antibody-mediated NK cell activation and FLU-v-specific IgG ( A ), IgG1 ( B ) and IgG3 ( C ) on days 0 and 42. Spearman rank order correlations were performed between the antibody-dependent NK cell activation assay, measuring the percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, and total IgG, IgG1, and IgG3 with correlation coefficients (r) and p -values shown. IgG data for this analysis were obtained from a previous report .
    Figure Legend Snippet: Correlation between antibody-mediated NK cell activation and FLU-v-specific IgG ( A ), IgG1 ( B ) and IgG3 ( C ) on days 0 and 42. Spearman rank order correlations were performed between the antibody-dependent NK cell activation assay, measuring the percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, and total IgG, IgG1, and IgG3 with correlation coefficients (r) and p -values shown. IgG data for this analysis were obtained from a previous report .

    Techniques Used: Activation Assay, Flow Cytometry



    Similar Products

    igg3 reference antibodies  (Athens Research)
    94
    Athens Research igg3 reference antibodies
    FLU-v IgG1 ( A ) and <t>IgG3</t> ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.
    Igg3 Reference Antibodies, supplied by Athens Research, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/igg3 reference antibodies/product/Athens Research
    Average 94 stars, based on 1 article reviews
    igg3 reference antibodies - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier
    immunoglobulin g3  (Athens Research)
    94
    Athens Research immunoglobulin g3
    FLU-v IgG1 ( A ) and <t>IgG3</t> ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.
    Immunoglobulin G3, supplied by Athens Research, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/immunoglobulin g3/product/Athens Research
    Average 94 stars, based on 1 article reviews
    immunoglobulin g3 - by Bioz Stars, 2026-03
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.

    Journal: Vaccines

    Article Title: FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans

    doi: 10.3390/vaccines13111084

    Figure Lengend Snippet: FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups on days 0, 42, and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo ( n = 26), and non-adjuvanted placebo ( n = 32). Box and whisker plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between time points within each group. Only significant differences are shown.

    Article Snippet: Wells in the standard rows were coated with human IgG1 or IgG3 reference antibodies (16-16-090707-1/16-16-090707-3, Athens Research, Athens, GA, USA), performing double decreasing serial dilutions starting at 1000 ng/mL up to 1.95 ng/mL.

    Techniques: Whisker Assay, MANN-WHITNEY

    Fold increase in FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups from day 0 to days 42 and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo (n = 26), and non-adjuvanted placebo ( n = 32). Box and whiskers plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. Fold change in IgG1 concentrations on day 42 and 180 is defined as the ratio of day 42 to day 0 and the ratio of day 180 to day 0, respectively. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between day 42 and 180 within each group. Significant differences are shown.

    Journal: Vaccines

    Article Title: FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans

    doi: 10.3390/vaccines13111084

    Figure Lengend Snippet: Fold increase in FLU-v IgG1 ( A ) and IgG3 ( B ) concentrations across all groups from day 0 to days 42 and 180. Data from the following groups are shown: adjuvanted FLU-v ( n = 52), non-adjuvanted FLU-v ( n = 58), adjuvanted placebo (n = 26), and non-adjuvanted placebo ( n = 32). Box and whiskers plot showing all individual values, 25th and 75th percentiles, and median. Whiskers represent ranges. Fold change in IgG1 concentrations on day 42 and 180 is defined as the ratio of day 42 to day 0 and the ratio of day 180 to day 0, respectively. The Mann–Whitney U test was used to compare different groups at each time point. The Wilcoxon signed-rank sum test was used to compare differences between day 42 and 180 within each group. Significant differences are shown.

    Article Snippet: Wells in the standard rows were coated with human IgG1 or IgG3 reference antibodies (16-16-090707-1/16-16-090707-3, Athens Research, Athens, GA, USA), performing double decreasing serial dilutions starting at 1000 ng/mL up to 1.95 ng/mL.

    Techniques: MANN-WHITNEY

    Antibody-mediated NK cell activation after adjuvanted and non-adjuvanted FLU-v vaccination. For this analysis, a subset of paired samples ( n = 50) from day 0 and day 42 was selected based on high IgG1 and IgG3 fold increases. Data from the following groups are shown: adjuvanted FLU-v ( n = 32), non-adjuvanted FLU-v ( n = 16), and non-adjuvanted placebo ( n = 2). Antibody-dependent NK cell activation, or percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, was measured in response to antibodies immobilized by plate-bound FLU-v ( A ) or non-related peptides used as negative controls ( B ). Medians ± 95% confidences intervals are shown. The Wilcoxon signed-rank sum test was used to compare differences between time points within each vaccine group. A Bonferroni test was used to correct for multiple comparisons, with a p value < 0.025 considered significant.

    Journal: Vaccines

    Article Title: FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans

    doi: 10.3390/vaccines13111084

    Figure Lengend Snippet: Antibody-mediated NK cell activation after adjuvanted and non-adjuvanted FLU-v vaccination. For this analysis, a subset of paired samples ( n = 50) from day 0 and day 42 was selected based on high IgG1 and IgG3 fold increases. Data from the following groups are shown: adjuvanted FLU-v ( n = 32), non-adjuvanted FLU-v ( n = 16), and non-adjuvanted placebo ( n = 2). Antibody-dependent NK cell activation, or percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, was measured in response to antibodies immobilized by plate-bound FLU-v ( A ) or non-related peptides used as negative controls ( B ). Medians ± 95% confidences intervals are shown. The Wilcoxon signed-rank sum test was used to compare differences between time points within each vaccine group. A Bonferroni test was used to correct for multiple comparisons, with a p value < 0.025 considered significant.

    Article Snippet: Wells in the standard rows were coated with human IgG1 or IgG3 reference antibodies (16-16-090707-1/16-16-090707-3, Athens Research, Athens, GA, USA), performing double decreasing serial dilutions starting at 1000 ng/mL up to 1.95 ng/mL.

    Techniques: Activation Assay, Flow Cytometry

    Correlation between antibody-mediated NK cell activation and FLU-v-specific IgG ( A ), IgG1 ( B ) and IgG3 ( C ) on days 0 and 42. Spearman rank order correlations were performed between the antibody-dependent NK cell activation assay, measuring the percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, and total IgG, IgG1, and IgG3 with correlation coefficients (r) and p -values shown. IgG data for this analysis were obtained from a previous report .

    Journal: Vaccines

    Article Title: FLU-v, a Broad-Spectrum Peptide-Based Influenza Vaccine, Induces NK Cell Activating IgG1 and IgG3 Subclass Antibodies in Humans

    doi: 10.3390/vaccines13111084

    Figure Lengend Snippet: Correlation between antibody-mediated NK cell activation and FLU-v-specific IgG ( A ), IgG1 ( B ) and IgG3 ( C ) on days 0 and 42. Spearman rank order correlations were performed between the antibody-dependent NK cell activation assay, measuring the percentage of GFP + CD107a + CD16 (V176) NK-92 cells by flow cytometry, and total IgG, IgG1, and IgG3 with correlation coefficients (r) and p -values shown. IgG data for this analysis were obtained from a previous report .

    Article Snippet: Wells in the standard rows were coated with human IgG1 or IgG3 reference antibodies (16-16-090707-1/16-16-090707-3, Athens Research, Athens, GA, USA), performing double decreasing serial dilutions starting at 1000 ng/mL up to 1.95 ng/mL.

    Techniques: Activation Assay, Flow Cytometry